Preclinical Assessment of Early Therapeutic Effect of Sunitinib on Renal Cell Carcinoma Using 18F-FLT PET in a Xenograft Model

2014 Fiscal Year Final Research Report

• Project/Area Number: 25861080
• Research Category: Grant-in-Aid for Young Scientists (B)
• Allocation Type: Multi-year Fund
• Research Field: Radiation science
• Research Institution: University of Fukui
• Principal Investigator: TAGA MINEKATSU 福井大学, 医学部附属病院, 助教 (00529349)
• Research Collaborator: OYAMA Nobuyuki 福井大学, 医学部附属病院, 講師 (20223977) ; KIYONO Yasushi 福井大学, 高エネルギー医学研究センター, 教授 (50305603) ; MORI Tetsuya 福井大学, 高エネルギー医学研究センター, 助教 (40397287)
• Project Period (FY): 2013-04-01 – 2015-03-31
• Keywords: 腎癌 / 分子標的薬 / 早期治療効果 / PET / FLT

Outline of Final Research Achievements

This study was undertaken to determine whether fluorothymidine(FLT) is useful for early response assessment in renal cell carcinoma (RCC) following sunitinib (SU) therapy using in vivo biodistribution (BD) and PET studies of tumor-bearing mice. ACHN were implanted in male mice. The mice were treated with SU or vehicle only. There was a significant increase of FLT in control group, while only a minimal change in SU group. The BD study showed a marked reduction of FLT uptake in tumors after SU treatment. PET showed the same tendency of BD study. Immunohistochemical analysis of the tumors revealed that the changes of FLT uptake were well correlated with those of tumor proliferation (PCNA index), tumor vascular density (CD34 density), VEGRF2expression, while no correlations were seen for apoptotic status up to 7 days of SU treatment. This result suggests that evaluation of FLT uptake in tumor may be an early predictor of anti-tumor effect of SU for RCC.

Free Research Field

医歯薬学